What OptiPin's sourced rule file says about Semaglutide with Insulin (Ozempic with insulin): the combination first, then what each one adds alone, then one bloodwork plan for both. It names markers and red flags, never doses.
This page describes a pair, not you. If you have chest pain, trouble breathing, weakness or numbness on one side, yellowing of your skin or eyes, or shaking, sweating and confusion that could be low blood sugar, get urgent medical care now. Nothing here is a dose, a protocol or a safety verdict.
What the rules say about the combination
1 rule fires only when both compounds are present. Each card is rendered from OptiPin's public, sourced rule file. Its labels show the evidence behind each claim (how we label evidence).
Interaction · label or pharmacokinetic evidence for the combination
GLP-1 drugs with insulin or a sulfonylurea: risk of lows Drug label
Flagged by: Semaglutide, Insulin
The semaglutide and tirzepatide labels warn of a higher risk of hypoglycemia, including severe hypoglycemia, when they are combined with insulin or a sulfonylurea.
The GLP-1 adds glucose lowering on top of a regimen that was set without it.
Markers to check
Home glucose readings, especially after the GLP-1 starts
HbA1c at the usual interval
How this is usually handled Drug label
This is usually handled by the prescriber adjusting the diabetes medication; speak to them before it starts or changes.
Get medical care for
Shakiness, sweating, confusion or a racing heart that improves with sugar
Glucose low enough that you cannot treat it yourself (emergency services)
Evidence
Strong for approved GLP-1 drugs (label interaction). For investigational incretin drugs such as retatrutide this is assumed from the shared mechanism, not shown.
Every marker the rules above name, listed once. Take it to your clinician or lab.
Home glucose readings, especially after the GLP-1 starts (GLP-1 drugs with insulin or a sulfonylurea: risk of lows)
HbA1c at the usual interval (GLP-1 drugs with insulin or a sulfonylurea: risk of lows)
Add anything else you run in the stack checker, which starts with this pair already filled in.
What each compound is
Semaglutide (Ozempic). A GLP-1 receptor agonist. Ozempic's label covers type 2 diabetes. More on Semaglutide.
Insulin. The rule covers the insulins in OptiPin's library: rapid-acting, regular, glargine and degludec. Insulin glargine (Lantus), for example, is a long-acting human insulin analog.
Log a cycle in OptiPin and it shows whether the stack converts to estradiol, which compounds are 19-nors or 17α-alkylated, when red cell count tends to climb and when your own production is shut down, each with the marker that reads it. All on-device.
The semaglutide and tirzepatide labels warn of a higher risk of hypoglycemia, including severe hypoglycemia, when they are combined with insulin or a sulfonylurea. The GLP-1 adds glucose lowering on top of a regimen that was set without it.
How is this usually handled on Semaglutide and Insulin?
This is usually handled by the prescriber adjusting the diabetes medication; speak to them before it starts or changes.
What is worth monitoring on Semaglutide and Insulin?
Home glucose readings, especially after the GLP-1 starts; HbA1c at the usual interval.
When should someone on Semaglutide and Insulin get medical care?
Shakiness, sweating, confusion or a racing heart that improves with sugar; Glucose low enough that you cannot treat it yourself (emergency services).
OptiPin